Commit Biologics ApS: Financial statements 2024
CVR: 42642649
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
Commit Biologics ApS (CVR 42642649) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -31,408,009 and a net result of DKK -39,360,775 compared with DKK -17,295,813 the year before. Equity in the 2024 report amounted to DKK 23,218,018. The solvency ratio was 95%. The company had 13 employees in the financial year.
- Gross Profit
- DKK -31,408,009
- Profit/Loss
- DKK -39,360,775
- Equity
- DKK 23,218,018
- Total Assets
- DKK 24,451,213
- Employees
- 13
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | -31.4 mio. | -39.4 mio. | 23.2 mio. | 13 |
| 2023 | - | -13.6 mio. | -17.3 mio. | 22.6 mio. | 10 |
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
As of December 23, 2024, Eva Van Overmeire has joined the board of directors of Commit Biologics ApS.
As of December 23, 2024, Janine Schuurman has joined the board of directors of Commit Biologics ApS.
Commit Biologics ApS has published its annual report for 2023. Gross profit came to DKK -13,580,251, and the net result was DKK -17,295,813.
About Commit Biologics ApS
Commit Biologics ApS is a Danish company of the type Anpartsselskab based in Aarhus C, founded in 2021. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Thomas Lars Andresen. The company's owners include Novo Holdings A/S, Commit Biologics Holding ApS and Bioqube Factory Fund I CommV. In 2025, the company reported a gross profit of DKK -23,365,247 and a net result of DKK -33,781,079 compared with DKK -39,360,775 the year before. Equity in the 2025 report amounted to DKK 37,898,027.